NDA 016608 · Novartis
Tegretol
Carbamazepine · Oral · Mood Stabilizer
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Jul 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1968
Mar 11, 1968
Approved uses
4
Original approval plus efficacy supplements
Registered trials
199
31 Phase 3, 6 recruiting
FAERS reports
64,113
55,674 serious, 5,490 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNINGS SERIOUS DERMATOLOGIC REACTIONS AND HLA-B*1502 ALLELE SERIOUS AND SOMETIMES FATAL DERMATOLOGIC REACTIONS, INCLUDING TOXIC EPIDERMAL NECROLYSIS (TEN) AND STEVENS-JOHNSON SYNDROME (SJS), HAVE BEEN REPORTED DURING TREATMENT WITH TEGRETOL. THESE REACTIONS ARE ESTIMATED TO OCCUR IN 1 TO 6 PER 10,000 NEW USERS IN COUNTRIES WITH MAINLY CAUCASIAN POPULATIONS, BUT THE RISK IN SOME ASIAN COUNTRIES IS ESTIMATED TO BE ABOUT 10 TIMES HIGHER. STUDIES IN PATIENTS OF CHINESE ANCESTRY HAVE FOUND A STRONG ASSOCIATION BETWEEN THE RISK OF DEVELOPING SJS/TEN AND THE PRESENCE OF HLA-B*1502, AN INHERITED ALLELIC VARIANT OF THE HLA-B GENE. HLA-B*1502 IS FOUND ALMOST EXCLUSIVELY IN PATIENTS WITH ANCESTRY ACROSS BROAD AREAS OF ASIA. PATIENTS WITH ANCESTRY IN GENETICALLY AT-RISK POPULATIONS SHOULD BE SCREENED FOR THE PRESENCE OF HLA-B*1502 PRIOR TO INITIATING TREATMENT WITH TEGRETOL. PATIENTS TESTING...
What it is approved for
From the label in effect Aug 20, 2026.
INDICATIONS AND USAGE Epilepsy Tegretol is indicated for use as an anticonvulsant drug. Evidence supporting efficacy of Tegretol as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: Partial seizures with complex symptomatology (psychomotor, temporal lobe). Patients with these seizures appear to show greater improvement than those with other types. Generalized tonic-clonic seizures (grand mal). Mixed seizure patterns which include the above, or other partial or generalized seizures. Absence seizures (petit mal) do not appear to be controlled by Tegretol (see PRECAUTIONS, General). Trigeminal Neuralgia Tegretol is indicated in the treatment of the pain associated with true trigeminal neuralgia. Beneficial results have also been reported in glossopharyngeal neuralgia. This drug is not a simple analgesic and should not be used for the relief of trivial aches or pains.
Mechanism: Mechanism of Action Tegretol has demonstrated anticonvulsant properties in rats and mice with electrically and chemically induced seizures. It appears to act by reducing polysynaptic responses and blocking the post-tetanic potentiation. Tegretol greatly reduces or abolishes pain induced by stimulation of the infraorbital nerve in cats and rats. It depresses thalamic potential and bulbar and polysynaptic reflexes, including the linguomandibular reflex in cats. Tegretol is chemically unrelated to other anticonvulsants or other drugs used to control the pain of trigeminal neuralgia. The...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 11, 1995 Supplement 59 · Efficacy
- Jul 31, 1987 Supplement 48 · Efficacy
- Jun 2, 1986 Supplement 54 · Efficacy
- Mar 11, 1968 Original approval · Type 1 - New Molecular Entity · priority review Review
1 products under this application
- TEGRETOL · CARBAMAZEPINE 200MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Carbamazepine" as an intervention, any sponsor and status, largest first.
- Levetiracetam Versus Standard Antiepileptic Drugs (Carbamazepine and Valproate) Used as Monotherapy in Patients With Newly Diagnosed EpilepsyPivotal-lookingCompleted
UCB PharmaUCB
NCT00175903 · 1,701 participants · Start Feb 2005 · Primary completion Oct 2007
Drug: Levetiracetam; Carbamazepine Controlled Release (CBZ-CR) and 1 more · For: Epilepsy
Sites: Adelaide, Australia; Bedford Park, Australia; Brisbane, Australia · 229 sites in all
- Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and OlderPivotal-lookingCompleted
NCT01243177 · 888 participants · Start Apr 2011 · Primary completion Jul 2015
Drug: Lacosamide; Carbamazepine-Controlled Release · For: Epilepsy; Monotherapy
Sites: Alabaster, Alabama; Huntsville, Alabama; Phoenix, Arizona · 184 sites in all
- A Study of the Effectiveness and Safety of Topiramate Compared With a Standard Therapy in Patients Newly Diagnosed With EpilepsyPivotal-lookingCompleted
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00236717 · 865 participants · Start Sep 1997
Drug: Topiramate; Carbamazepine; Valproate · For: Epilepsy; Seizures
- Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset SeizuresPivotal-lookingCompleted
Bial - Portela C S.A.Industry
NCT01162460 · 815 participants · Start Dec 2010 · Primary completion Sep 2016
Drug: Eslicarbazepine acetate (BIA 2-093) · For: Epilepsy
Sites: S. Mamede Do Coronado, Portugal
- Does Gabapentin and Lamotriginel Have Significantly Fewer Side-effects While Providing Equal or Better Seizure Control Than the Current Drug Choice, Carbamazepine, for the Treatment of Seizures in the Elderly.Pivotal-lookingCompleted
US Department of Veterans AffairsFederal agency
NCT00007670 · 720 participants · Start Jan 1998
Drug: Carbamazepine; Gabapentin and 1 more · For: Seizures
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 20 sites in all
- Levetiracetam Versus Carbamazepine in Post-Stroke Late Onset CrisisPivotal-lookingStatus unknown
Scienze Neurologiche OspedaliereAcademic, hospital or other
NCT00542802 · 630 participants (planned) · Start Sep 2007 · Primary completion Jun 2009
Drug: Levetiracetam; Carbamazepine · For: Epileptic Seizures; Stroke
Sites: Novi Ligure, Italy; Cuneo, Italy; Genova, Italy · 24 sites in all
- A Double-blind Study to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial EpilepsyPivotal-lookingCompleted
Eisai Inc.Eisai
NCT00477295 · 583 participants · Start May 2007 · Primary completion Dec 2010
Drug: Zonisamide; Carbamazepine · For: Epilepsy
Sites: Camperdown, Australia; Clayton, Australia; Fitzroy, Australia · 79 sites in all
- Monotherapy With Levetiracetam in Newly Diagnosed Patients Suffering From EpilepsyPivotal-lookingCompleted
UCB PharmaUCB
NCT00150735 · 580 participants · Start Jun 2002 · Primary completion Jul 2005
Drug: LEVETIRACETAM · For: Generalized Epilepsy
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective4,921
- drug interaction3,445
- seizure3,415
- fall2,937
- dizziness2,757
- toxicity to various agents2,741
- off label use2,709
- pyrexia2,675
- nausea2,566
- vomiting2,471
- fatigue2,354
- convulsion2,345
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,434 |
| 2005 | 1,784 |
| 2006 | 1,707 |
| 2007 | 1,643 |
| 2008 | 1,892 |
| 2009 | 2,340 |
| 2010 | 2,297 |
| 2011 | 2,506 |
| 2012 | 3,243 |
| 2013 | 2,514 |
| 2014 | 2,798 |
| 2015 | 3,402 |
| 2016 | 3,483 |
| 2017 | 3,586 |
| 2018 | 4,321 |
| 2019 | 4,062 |
| 2020 | 3,380 |
| 2021 | 3,724 |
| 2022 | 3,244 |
| 2023 | 2,864 |
| 2024 | 2,857 |
| 2025 | 2,849 |
| 2026 | 2,176 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Tegretol (Carbamazepine)
2024 spending
$11.6M
Beneficiaries
3,532
21,732 claims
Per beneficiary
$3,279
$2.67 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $13,773,591 |
| 2021 | $13,081,659 |
| 2022 | $12,344,580 |
| 2023 | $13,119,143 |
| 2024 | $11,581,199 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials.
Kishi T, Ikuta T, Matsuda Y, et al. · Mol Psychiatry 2022 · Systematic Review, Research Support, Non-U.S. Gov't
- Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials.
Kishi T, Ikuta T, Matsuda Y, et al. · Mol Psychiatry 2021 · Network Meta-Analysis, Research Support, Non-U.S. Gov't
- The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An update on management of behavioral and psychological symptoms in dementia.
Chen A, Copeli F, Metzger E, et al. · Psychiatry Res 2021 · Meta-Analysis, Systematic Review
- Carbamazepine for schizophrenia.
Leucht S, Helfer B, Dold M, et al. · Cochrane Database Syst Rev 2014 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Efficacy and safety of pharmacological treatments in borderline personality disorder: A systematic review and network meta-analysis.
Gerolymos C, Garosi A, Boyer L, et al. · Mol Psychiatry 2026 · Systematic Review, Network Meta-Analysis
- Comparative efficacy and safety of pharmacotherapies for alcohol withdrawal: a systematic review and network meta-analysis.
Bahji A, Bach P, Danilewitz M, et al. · Addiction 2022 · Systematic Review, Network Meta-Analysis
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.